{
  "label": "clinical_signal_03_dx_vaccine_immunogenicity_009",
  "artifact_type": "distractor_episode",
  "artifact_id": "sha256:95c825ed6c63d95ed814c30e7624c02a486c12d7c6d4d43978c6ad92ae5052f5",
  "input_ids": [
    "sha256:b4ba5337b06c8de68ac3315db1a4f6980c5bd48efd529c3914f30297d6afd329",
    "sha256:b9a5f4498416bfb2148e106e9d25ca838481bb56025a18e16baf31718f4ee4a2"
  ],
  "prompt_id": null,
  "model_config": null,
  "created_at": "2026-02-17T12:00:34.218121",
  "content": "## 2024-04-29 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 106\n- Active: 104\n- Screen Failures Cumulative: 12\n- Withdrawals Cumulative: 2\n\n### Enrollment By Dose Group\n- Low Dose: 25\n- Mid Dose: 25\n- High Dose: 28\n- Placebo: 28\n\n### Immunogenicity By Group\n- Low Dose\n  - IgG Titer (GMU) Mean: 56.0\n  - IgG Titer (GMU) SD: 6.0\n  - IgM Titer (GMU) Mean: 19.1\n  - IgM Titer (GMU) SD: 4.0\n  - Neutralizing Ab ID50 Mean: 94.3\n  - Neutralizing Ab ID50 SD: 10.0\n  - CD4 Response (SFC per 10^6) Mean: 136.0\n  - CD4 Response (SFC per 10^6) SD: 15.0\n  - CD8 Response (SFC per 10^6) Mean: 97.0\n  - CD8 Response (SFC per 10^6) SD: 11.0\n  - Seroconversion Percentage: 25.1\n- Mid Dose\n  - IgG Titer (GMU) Mean: 94.6\n  - IgG Titer (GMU) SD: 9.6\n  - IgM Titer (GMU) Mean: 29.4\n  - IgM Titer (GMU) SD: 6.4\n  - Neutralizing Ab ID50 Mean: 147.2\n  - Neutralizing Ab ID50 SD: 16.0\n  - CD4 Response (SFC per 10^6) Mean: 212.0\n  - CD4 Response (SFC per 10^6) SD: 24.0\n  - CD8 Response (SFC per 10^6) Mean: 161.0\n  - CD8 Response (SFC per 10^6) SD: 18.0\n  - Seroconversion Percentage: 32.4\n- High Dose\n  - IgG Titer (GMU) Mean: 121.7\n  - IgG Titer (GMU) SD: 13.2\n  - IgM Titer (GMU) Mean: 38.8\n  - IgM Titer (GMU) SD: 8.8\n  - Neutralizing Ab ID50 Mean: 200.1\n  - Neutralizing Ab ID50 SD: 22.0\n  - CD4 Response (SFC per 10^6) Mean: 300.0\n  - CD4 Response (SFC per 10^6) SD: 33.0\n  - CD8 Response (SFC per 10^6) Mean: 216.0\n  - CD8 Response (SFC per 10^6) SD: 24.0\n  - Seroconversion Percentage: 51.1\n- Placebo\n  - IgG Titer (GMU) Mean: 6.5\n  - IgG Titer (GMU) SD: 1.2\n  - IgM Titer (GMU) Mean: 3.5\n  - IgM Titer (GMU) SD: 0.8\n  - Neutralizing Ab ID50 Mean: 17.2\n  - Neutralizing Ab ID50 SD: 2.0\n  - CD4 Response (SFC per 10^6) Mean: 25.0\n  - CD4 Response (SFC per 10^6) SD: 3.0\n  - CD8 Response (SFC per 10^6) Mean: 25.0\n  - CD8 Response (SFC per 10^6) SD: 2.0\n  - Seroconversion Percentage: 4.5\n\n### Injection Site Reactions\n- Pain Percentage: 54.3\n- Erythema Percentage: 21.9\n- Swelling Percentage: 17.9\n- Induration Percentage: 7.8\n- Mean Pain Duration (Hours): 39.4\n\n### Systemic Reactogenicity\n- Fever Percentage: 12.8\n- Fatigue Percentage: 40.6\n- Myalgia Percentage: 23.2\n- Headache Percentage: 29.7\n- Chills Percentage: 8.4\n\n### Safety Labs\n- WBC (K) Mean: 6.5\n- WBC (K) SD: 1.7\n- Lymphocyte Percentage Mean: 25.0\n- Lymphocyte Percentage SD: 4.1\n- Neutrophil Percentage Mean: 46.9\n- Neutrophil Percentage SD: 8.0\n- Platelets (K) Mean: 220\n- Platelets (K) SD: 41\n- CRP (mg/L) Mean: 5.7\n- CRP (mg/L) SD: 1.1\n- Hemoglobin (g/dL) Mean: 13.4\n- Hemoglobin (g/dL) SD: 1.1\n\n### Adverse Events\n- AE ID: VI-AE-0932, Description: myalgia, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: low_dose\n- AE ID: VI-AE-0962, Description: lymphadenopathy, Grade: 2, Relatedness: possibly related, Resolved: true, Dose Group: low_dose\n- AE ID: VI-AE-0971, Description: chills, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: mid_dose\n\n### Events\n- T-cell assay batch B09 processed, results QC'd\n- DSMB safety review teleconference completed\n\n### Notes\n- Week 9: Immunogenicity assessments on schedule. 106 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.",
  "metadata": {
    "episode_type": "distractor",
    "theme": "vaccine_immunogenicity",
    "theme_index": 1,
    "local_index": 9,
    "scope_id": "clinical_signal_03",
    "layer_name": "distractor_episodes",
    "layer_level": 2,
    "build_fingerprint": {
      "scheme": "synix:build:v1",
      "digest": "86d399f4ea18a5663d6624e24cd8b639bcd4c45932ccbdc83c5254419dc5a8df",
      "components": {
        "transform": "a88665a5359d5ac5d2c858c77a2a19318c209adeea6fae2b838d79e11f6aba2b",
        "inputs": "c06ced136368edaf"
      }
    },
    "transform_fingerprint": {
      "scheme": "synix:transform:v2",
      "digest": "a88665a5359d5ac5d2c858c77a2a19318c209adeea6fae2b838d79e11f6aba2b",
      "components": {
        "transform_id": "01137a4997b78f86",
        "source": "c42d9c6282d5331f",
        "model": "1e2ccf75e96d7ee7"
      }
    }
  }
}